1. A third-year medical student is reviewing the mechanism of chloramphenicol for an upcoming pharmacology examination. She asks her attending how chloramphenicol prevents bacterial protein synthesis at the molecular level. Which of the following best describes the primary mechanism by which chloramphenicol exerts its antibacterial effect?
A) It binds to the 30S ribosomal subunit and blocks attachment of aminoacyl-tRNA to the A site
B) It binds to the 23S rRNA of the 50S ribosomal subunit at the peptidyl transferase center, preventing peptide bond formation
C) It inhibits formation of the 70S initiation complex by blocking assembly of the 30S and 50S subunits before translation begins
D) It binds to the 50S subunit and causes premature release of the nascent peptide chain from the ribosome
E) It intercalates into bacterial DNA at the replication fork, blocking RNA polymerase progression
ANSWER: B
Rationale:
Chloramphenicol binds reversibly to the 23S rRNA component of the 50S ribosomal subunit at the peptidyl transferase center — the catalytic site that forms the peptide bond between the growing polypeptide chain and the incoming aminoacyl-tRNA. By occupying this site, chloramphenicol prevents the peptidyl transferase reaction from occurring, halting elongation of the nascent peptide chain. This mechanism produces a bacteriostatic effect against most organisms, though chloramphenicol can be bactericidal against H. influenzae, N. meningitidis, and S. pneumoniae at clinical concentrations.
Option A: Option A is incorrect because binding to the 30S subunit to block aminoacyl-tRNA attachment to the A site is the mechanism of tetracyclines, not chloramphenicol; chloramphenicol acts on the 50S subunit.
Option C: Option C is incorrect because inhibiting 70S initiation complex formation by blocking 30S/50S assembly before translation begins is the mechanism of the oxazolidinones (linezolid, tedizolid) — a fundamentally different and pre-elongation step compared to chloramphenicol's action during peptide bond formation.
Option D: Option D is incorrect because premature release of the nascent peptide chain is not the mechanism of chloramphenicol; no clinically used antibiotic class works primarily through this mechanism as described.
Option E: Option E is incorrect because intercalating into bacterial DNA to block RNA polymerase is not a ribosomal mechanism at all; chloramphenicol acts exclusively at the ribosome and has no direct effect on DNA replication or transcription.
2. A resident reviewing antibacterial spectrum notes that chloramphenicol is generally classified as bacteriostatic, yet is described as bactericidal against certain pathogens at achievable clinical concentrations. Which of the following organisms is correctly paired with chloramphenicol's bactericidal activity?
A) Methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecium
B) Pseudomonas aeruginosa and Klebsiella pneumoniae
C) Bacteroides fragilis and Clostridium perfringens
D) Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae
E) Salmonella typhi and Escherichia coli
ANSWER: D
Rationale:
Chloramphenicol is bactericidal at clinical concentrations against H. influenzae, N. meningitidis, and S. pneumoniae — three of the most common causes of bacterial meningitis. This bactericidal activity against these specific pathogens, combined with chloramphenicol's exceptional CNS penetration, historically made it a first-line agent for bacterial meningitis before cephalosporins became available and remains a reason it is used for meningitis in beta-lactam-allergic patients in resource-limited settings. Against most other organisms in its spectrum, chloramphenicol is bacteriostatic.
Option A: Option A is incorrect because chloramphenicol is not bactericidal and does not have reliable activity against MRSA; oxazolidinones or glycopeptides are used for MRSA, not chloramphenicol.
Option B: Option B is incorrect because chloramphenicol does not have reliable or clinically useful activity against P. aeruginosa or Klebsiella at standard doses, and bactericidal activity against these organisms is not a described property.
Option C: Option C is incorrect because while chloramphenicol has activity against B. fragilis and certain anaerobes, this combination is not the classic teaching point for its bactericidal spectrum; anaerobic coverage is clinically useful but does not reflect the bactericidal organisms it is known for.
Option E: Option E is incorrect because while chloramphenicol has activity against S. typhi, its effect is bacteriostatic against Enterobacteriaceae including S. typhi and E. coli, not bactericidal; E. coli coverage also does not reflect a clinical strength of the drug.
3. A 34-year-old patient with a severe penicillin allergy (anaphylaxis to amoxicillin) presents with bacterial meningitis. The infectious disease team considers chloramphenicol as an alternative agent. A medical student asks why chloramphenicol is considered suitable for this indication despite its toxicity profile. Which pharmacokinetic property most directly supports the use of chloramphenicol in bacterial meningitis?
A) Chloramphenicol achieves cerebrospinal fluid concentrations of approximately 30 to 50% of simultaneous plasma concentrations even in the absence of meningeal inflammation, with levels approaching plasma concentrations when the meninges are inflamed
B) Chloramphenicol undergoes active transport across the blood-brain barrier via P-glycoprotein efflux pump reversal, concentrating it in the CNS relative to plasma
C) Chloramphenicol's high degree of protein binding (>90%) creates a reservoir effect that sustains therapeutic drug levels in the CSF for 24 to 48 hours after each dose
D) Chloramphenicol is converted to an active metabolite in the choroid plexus that has 10-fold greater antibacterial potency than the parent compound
E) Chloramphenicol penetrates the blood-brain barrier exclusively through inflamed meninges, achieving therapeutic CSF levels only in patients with active meningitis
ANSWER: A
Rationale:
Chloramphenicol's most clinically significant pharmacokinetic property is its exceptional CNS penetration. It achieves CSF concentrations of approximately 30 to 50% of simultaneous plasma concentrations even without meningeal inflammation — superior to most beta-lactams — and CSF levels approach plasma levels when the meninges are inflamed. This penetration is due to chloramphenicol's lipophilicity and lack of ionization at physiologic pH, which allow it to cross lipid bilayers including the blood-brain barrier by passive diffusion without requiring active transport. This property, combined with bactericidal activity against H. influenzae, N. meningitidis, and S. pneumoniae, is the pharmacological basis for its use in meningitis when beta-lactams cannot be used.
Option B: Option B is incorrect because chloramphenicol crosses the blood-brain barrier by passive diffusion based on its lipophilic physicochemical properties, not by active transport or P-glycoprotein reversal; the mechanism described does not apply to chloramphenicol.
Option C: Option C is incorrect because chloramphenicol is not highly protein bound (approximately 50 to 60%), and high protein binding would actually reduce CNS penetration rather than create a sustained CNS reservoir; the mechanism described is pharmacologically incorrect for this drug.
Option D: Option D is incorrect because chloramphenicol is not converted to a more potent active metabolite in the choroid plexus; it is metabolized primarily by hepatic glucuronidation to an inactive conjugate, and no CNS-specific bioactivation pathway exists for this drug.
Option E: Option E is incorrect because chloramphenicol penetrates the CNS well even in the absence of meningeal inflammation — this is in fact one of its pharmacokinetic advantages over drugs that rely on inflammation-enhanced penetration; restriction to inflamed meninges describes a limitation of drugs like aminoglycosides, not an advantage of chloramphenicol.
4. A neonatologist is counseling a resident about the pharmacological basis of gray baby syndrome, a potentially fatal toxicity observed when chloramphenicol is administered to neonates at doses appropriate for older children or adults. Which of the following best explains the mechanism underlying this toxicity?
A) Neonatal renal tubular secretion is immature, causing chloramphenicol to accumulate in the bloodstream because its primary elimination route is unchanged renal excretion
B) Neonates have increased expression of intestinal P-glycoprotein that traps chloramphenicol in enterocytes, creating toxic local gut concentrations that cause cardiovascular collapse
C) Neonatal hepatic glucuronidation pathways are immature and substantially underdeveloped, preventing the normal conjugation and inactivation of chloramphenicol, which accumulates to toxic levels that inhibit mitochondrial protein synthesis in cardiac and skeletal muscle
D) Neonatal plasma albumin has reduced affinity for chloramphenicol compared to adult albumin, increasing the free fraction of the drug and producing toxicity at lower total plasma concentrations
E) Neonates have higher expression of the 50S ribosomal peptidyl transferase subunit than adults, making their ribosomes more sensitive to chloramphenicol's bacteriostatic mechanism at standard doses
ANSWER: C
Rationale:
Gray baby syndrome results from immature hepatic glucuronidation in neonates, particularly premature infants. Chloramphenicol is primarily metabolized in the liver by glucuronosyltransferase enzymes that conjugate the drug to an inactive glucuronide for renal excretion. In neonates, these glucuronidation pathways are not yet developed, so standard weight-based doses lead to chloramphenicol accumulation rather than normal metabolism and clearance. The accumulated drug inhibits mitochondrial protein synthesis in cardiac and skeletal muscle — the same biochemical mechanism responsible for its antibacterial activity — producing the syndrome characterized by abdominal distension, vomiting, cyanosis, ashen gray skin color, and cardiovascular collapse. The condition is potentially fatal. When chloramphenicol must be used in neonates, doses must be substantially reduced (25 mg/kg/day) with serum level monitoring.
Option A: Option A is incorrect because chloramphenicol is not primarily eliminated unchanged by renal excretion; it is metabolized by hepatic glucuronidation to an inactive metabolite before excretion, so renal immaturity is not the primary mechanism of accumulation in gray baby syndrome.
Option B: Option B is incorrect because P-glycoprotein expression in neonatal enterocytes does not produce toxic chloramphenicol accumulation; chloramphenicol is absorbed from the gut, and the described mechanism bears no relationship to gray baby syndrome pathophysiology.
Option D: Option D is incorrect because while neonatal protein binding characteristics differ from adults, reduced albumin binding is not the mechanism of gray baby syndrome; the toxicity is due to reduced metabolic elimination capacity, not increased free fraction at standard concentrations.
Option E: Option E is incorrect because the toxicity of gray baby syndrome is due to inhibition of human mitochondrial protein synthesis through the same ribosomal mechanism — not enhanced sensitivity of bacterial-type ribosomes — and this explanation conflates human mitochondrial toxicity with antibacterial receptor pharmacology.
5. An infectious disease pharmacist is explaining chloramphenicol pharmacokinetics to a pharmacy resident. The pharmacist notes that the intravenous formulation of chloramphenicol has a pharmacokinetic disadvantage compared to the oral form for achieving consistent drug exposure. Which of the following best explains this difference?
A) Oral chloramphenicol undergoes extensive first-pass hepatic metabolism that generates an active metabolite with greater antibacterial potency than the parent compound administered intravenously
B) Intravenous chloramphenicol bypasses intestinal absorption, which is required to activate a transporter that distributes the drug to infected tissues
C) Oral chloramphenicol chelates divalent cations in the gastrointestinal tract, forming a complex that is more slowly absorbed and provides sustained plasma levels compared to an IV bolus
D) Intravenous chloramphenicol is administered at a lower milligram dose than the oral formulation due to concerns about rapid peak concentrations causing direct cardiac toxicity
E) The intravenous formulation is chloramphenicol succinate, a prodrug that must be hydrolyzed by plasma and tissue esterases to the active base form; this hydrolysis is variable and incomplete, resulting in lower and less predictable plasma concentrations than those achieved with oral dosing of the active base compound
ANSWER: E
Rationale:
Chloramphenicol for intravenous use is formulated as chloramphenicol succinate, a water-soluble prodrug that must be hydrolyzed by plasma and tissue esterases to release the active chloramphenicol base. This hydrolysis step is variable among patients and is often incomplete, with a portion of the succinate ester excreted unchanged in the urine before hydrolysis occurs. As a result, IV chloramphenicol succinate produces lower and less predictable plasma levels than oral chloramphenicol base, which is absorbed directly with approximately 75 to 90% bioavailability. This prodrug limitation means that serum level monitoring is especially important when the IV formulation is used, and in some clinical scenarios oral dosing may actually provide more reliable drug exposure if the patient can take medications by mouth.
Option A: Option A is incorrect because oral chloramphenicol does not generate a more active metabolite through first-pass metabolism; hepatic metabolism produces glucuronide conjugates that are inactive, and the oral bioavailability advantage relates to direct absorption of the active form, not metabolic activation.
Option B: Option B is incorrect because there is no intestinal transporter that must be activated by gastrointestinal absorption for chloramphenicol distribution; the drug crosses membranes by passive diffusion, and intestinal absorption is not a prerequisite for tissue distribution from IV administration.
Option C: Option C is incorrect because chelation of divalent cations with chloramphenicol is not a pharmacokinetic mechanism; cation chelation is a characteristic of tetracyclines, not chloramphenicol, and does not explain the IV-versus-oral difference.
Option D: Option D is incorrect because the dose of chloramphenicol is not routinely reduced for intravenous administration to prevent cardiac toxicity; the cardiovascular toxicity (seen in gray baby syndrome) is related to toxic accumulation from metabolic impairment, not to normal IV peak concentrations in adults, and standard IV and oral doses are similar.
6. A general internist is counseling a patient about the risks of chloramphenicol therapy. The patient asks whether regular blood tests during treatment can prevent the fatal bone marrow complication associated with the drug. Which of the following statements about chloramphenicol-associated aplastic anemia is most accurate?
A) Aplastic anemia from chloramphenicol is dose-dependent and predictably occurs at plasma concentrations above 25 mcg/mL; serum level monitoring is therefore an effective preventive strategy
B) Chloramphenicol-associated aplastic anemia is an idiosyncratic reaction that is unrelated to dose or plasma concentration, occurring at a rate of approximately 1 in 25,000 to 1 in 40,000 courses; it cannot be predicted by serum level monitoring and is not prevented by dose reduction
C) Aplastic anemia is the most common hematologic toxicity of chloramphenicol and typically presents within the first 48 to 72 hours of initiating therapy as an acute hypersensitivity reaction
D) Chloramphenicol-associated aplastic anemia is caused by the same mitochondrial protein synthesis inhibition mechanism that produces the drug's antibacterial effect and is therefore mechanistically predictable and reversible with drug discontinuation
E) The risk of aplastic anemia is confined to patients who receive chloramphenicol for more than 14 consecutive days; short courses of 7 days or fewer carry no meaningful risk of this complication
ANSWER: B
Rationale:
Chloramphenicol-associated aplastic anemia is an idiosyncratic reaction with no relationship to dose or plasma concentration. It occurs at a rate of approximately 1 in 25,000 to 1 in 40,000 courses of treatment and typically presents weeks to months after drug exposure — often after the treatment course has been completed — making causality difficult to recognize. The mechanism involves toxic effects of chloramphenicol or its metabolites (particularly the nitroso-chloramphenicol reduction product) on hematopoietic stem cells, producing irreversible destruction of the bone marrow. Once established, aplastic anemia carries a mortality exceeding 50% without bone marrow transplantation or immunosuppressive therapy. Because the reaction is idiosyncratic and dose-independent, serum level monitoring cannot predict or prevent it, and dose reduction has no protective effect. This is the primary reason chloramphenicol use has been dramatically curtailed in high-income countries.
Option A: Option A is incorrect because the described characteristics — dose-dependence and levels above 25 mcg/mL — describe chloramphenicol's reversible bone marrow suppression, which is a separate and mechanistically distinct toxicity from aplastic anemia; conflating these two conditions is a critical clinical error.
Option C: Option C is incorrect because aplastic anemia is not the most common hematologic toxicity (reversible myelosuppression is more common), does not present within 48 to 72 hours, and is not an acute hypersensitivity reaction; its delayed onset weeks to months after exposure is a defining feature.
Option D: Option D is incorrect because aplastic anemia is not mechanistically related to mitochondrial protein synthesis inhibition in the way that reversible myelosuppression is; aplastic anemia involves hematopoietic stem cell destruction by reactive metabolites through a poorly understood toxic mechanism, and it is irreversible — not reversed by drug discontinuation.
Option E: Option E is incorrect because aplastic anemia has been reported even after brief courses of chloramphenicol; there is no safe duration threshold below which the idiosyncratic risk is eliminated, and this misconception could lead to false reassurance with short-course use.
7. A 52-year-old patient receiving chloramphenicol for refractory brain abscess develops anemia, leukopenia, and thrombocytopenia after 3 weeks of therapy. His serum chloramphenicol level is 28 mcg/mL. Bone marrow examination shows vacuolated erythroid and myeloid precursors with a reduced reticulocyte count. The treating physician discontinues chloramphenicol. What is the most likely clinical course of this hematologic toxicity?
A) The pancytopenia will progress despite drug discontinuation because hematopoietic stem cell destruction is already irreversible, and bone marrow transplantation will be required for recovery
B) Partial recovery of only the erythroid line is expected; linezolid cross-toxicity will prevent platelet and leukocyte recovery regardless of treatment changes
C) The pancytopenia represents an early sign of aplastic anemia and will result in fatal bone marrow failure in approximately 50% of affected patients within 6 months
D) The pancytopenia is dose-dependent reversible bone marrow suppression related to elevated plasma concentrations and mitochondrial protein synthesis inhibition in bone marrow precursors; complete recovery is expected upon drug discontinuation
E) The abnormalities will resolve only after pyridoxine (vitamin B6) supplementation is added, as the mechanism involves B6-dependent mitochondrial enzyme inhibition in hematopoietic cells
ANSWER: D
Rationale:
This presentation is consistent with chloramphenicol's dose-dependent, reversible bone marrow suppression — distinct from the idiosyncratic aplastic anemia. The key features identifying this as reversible toxicity are: the supratherapeutic serum level (28 mcg/mL, above the toxicity threshold of approximately 25 mcg/mL), the bone marrow morphology showing vacuolation of erythroid and myeloid precursors with decreased reticulocytes (the characteristic picture of mitochondrial toxicity in hematopoietic precursors), and the involvement of all three cell lines in a predictable, dose-dependent pattern. This toxicity occurs through the same mechanism as the antibacterial effect — inhibition of mitochondrial protein synthesis, because mitochondrial ribosomes are structurally similar to bacterial 70S ribosomes. Complete recovery is expected upon drug discontinuation as the drug is cleared and mitochondrial function in bone marrow precursors is restored.
Option A: Option A is incorrect because this description — irreversible stem cell destruction requiring transplantation — characterizes idiosyncratic aplastic anemia, not the reversible dose-dependent suppression shown here; the elevated serum level and morphological findings point to a pharmacokinetic toxicity, not an idiosyncratic reaction.
Option B: Option B is incorrect because chloramphenicol's reversible suppression affects all cell lines equally through a shared mitochondrial mechanism, and there is no linezolid cross-toxicity mechanism that selectively prevents recovery of non-erythroid lines; linezolid also causes reversible myelosuppression but this patient is not on linezolid.
Option C: Option C is incorrect because aplastic anemia is an idiosyncratic reaction unrelated to dose or levels; the presence of a supratherapeutic serum level and the specific bone marrow morphology described here identify this as the reversible form, not aplastic anemia, and the 50% mortality figure applies to aplastic anemia, not to this presentation.
Option E: Option E is incorrect because pyridoxine supplementation is not the treatment or mechanistic correction for chloramphenicol's reversible bone marrow suppression; pyridoxine has a role in mitigating linezolid-associated neuropathy in long courses for drug-resistant tuberculosis, not in reversing chloramphenicol myelosuppression.
8. A 61-year-old patient with a seizure disorder managed on phenytoin and atrial fibrillation managed on warfarin requires chloramphenicol for a serious infection. The pharmacist flags this combination as high-risk. Which of the following best explains the drug interaction mechanism and expected clinical consequences?
A) Chloramphenicol is a potent inhibitor of CYP2C19 and also inhibits CYP2C9, reducing the metabolism of both phenytoin and S-warfarin; co-administration is expected to produce phenytoin toxicity (nystagmus, ataxia, altered consciousness) and markedly enhanced anticoagulation with bleeding risk
B) Chloramphenicol induces CYP3A4, accelerating the metabolism of phenytoin and warfarin and reducing their plasma concentrations to subtherapeutic levels, requiring dose increases of both agents during co-administration
C) Chloramphenicol displaces phenytoin and warfarin from plasma albumin binding sites, acutely increasing their free fractions and producing transient toxicity that resolves within 24 hours as redistribution occurs
D) Chloramphenicol and phenytoin compete for renal tubular secretion, causing accumulation of both drugs; warfarin is not affected because it is exclusively metabolized by the liver
E) Chloramphenicol inhibits intestinal P-glycoprotein, increasing oral bioavailability of both phenytoin and warfarin by approximately 30 to 40%, necessitating dose reduction of both agents to maintain therapeutic levels
ANSWER: A
Rationale:
Chloramphenicol is a potent inhibitor of CYP2C19 and also inhibits CYP2C9 and CYP3A4 to a lesser degree. CYP2C19 is the primary enzyme responsible for metabolizing phenytoin; chloramphenicol co-administration reduces phenytoin clearance, causing phenytoin to accumulate to toxic concentrations even when the patient is receiving a previously well-tolerated dose. Phenytoin toxicity manifests as nystagmus, ataxia, diplopia, and altered consciousness — a clinically recognizable syndrome. S-warfarin (the more pharmacodynamically active enantiomer) is primarily metabolized by CYP2C9; chloramphenicol's inhibition of CYP2C9 reduces warfarin clearance and substantially enhances anticoagulation, creating bleeding risk at previously stable warfarin doses. Both interactions are clinically significant and require either avoidance of combination therapy or very close monitoring of phenytoin levels and INR (international normalized ratio) during concurrent use.
Option B: Option B is incorrect because chloramphenicol is an enzyme inhibitor, not an inducer; it does not accelerate CYP metabolism of phenytoin or warfarin, and the consequence is toxicity from accumulation, not subtherapeutic levels from enhanced clearance.
Option C: Option C is incorrect because protein displacement interactions, while theoretically possible, do not produce sustained clinical toxicity in practice; free drug that is displaced rapidly redistributes into tissues, and the net effect on total drug concentrations and clinical response is generally negligible — protein displacement is not the mechanism of this clinically important interaction.
Option D: Option D is incorrect because phenytoin and chloramphenicol are not eliminated by renal tubular secretion to a clinically relevant extent; phenytoin is almost entirely hepatically metabolized, and the interaction is metabolic, not competitive renal elimination; the statement about warfarin being unaffected is also incorrect.
Option E: Option E is incorrect because inhibition of intestinal P-glycoprotein (which reduces efflux of drugs back into the gut lumen) is not the mechanism of chloramphenicol's interaction with phenytoin or warfarin; the interaction is mediated by hepatic CYP enzyme inhibition, not gastrointestinal absorption enhancement.
9. A senior resident on an infectious disease rotation is asked to identify the remaining clinical scenarios in high-income countries where systemic chloramphenicol use is still considered appropriate. Which of the following best describes the current clinical role of systemic chloramphenicol in high-income country settings?
A) Chloramphenicol is the preferred first-line agent for community-acquired pneumonia caused by atypical organisms, particularly Legionella pneumophila, because of its superior intracellular penetration
B) Chloramphenicol is used as standard empiric coverage for septic shock when the causative organism is unknown, due to its exceptionally broad spectrum covering both Gram-positive and Gram-negative pathogens
C) Systemic chloramphenicol is reserved for narrow indications including bacterial meningitis in patients with severe beta-lactam allergy who cannot receive cephalosporins, typhoid fever with multidrug-resistant Salmonella typhi where safer alternatives are unavailable, and brain abscess where its CNS penetration combined with anaerobic coverage provides treatment options that are otherwise difficult to achieve
D) Chloramphenicol is used as routine prophylaxis in immunocompromised patients undergoing hematopoietic stem cell transplantation, because its myelosuppressive effects can be exploited to reduce host immune rejection of donor marrow
E) Chloramphenicol is the agent of choice for MRSA infections in patients with renal failure who cannot receive vancomycin, because its hepatic metabolism avoids the need for renal dose adjustment
ANSWER: C
Rationale:
In high-income countries, the risk of aplastic anemia has dramatically narrowed systemic chloramphenicol use to a small number of specific indications where no safer alternative exists or where its pharmacokinetic profile provides an advantage that safer drugs cannot match. These include: bacterial meningitis in patients with severe beta-lactam allergy (anaphylaxis) who cannot safely receive cephalosporins, where chloramphenicol's exceptional CNS penetration and bactericidal activity against the common meningeal pathogens remain relevant; typhoid fever caused by multidrug-resistant S. typhi in regions or clinical scenarios where fluoroquinolones and third-generation cephalosporins are not options; and brain abscess, where the combination of CNS penetration, anaerobic coverage (including B. fragilis), and broad Gram-positive/Gram-negative activity is difficult to replicate with a single safer agent. Topical formulations remain widely used for conjunctivitis without systemic risk concerns.
Option A: Option A is incorrect because chloramphenicol is not used for Legionella pneumonia; macrolides (azithromycin) and fluoroquinolones are the agents of choice for Legionella and atypical pneumonia pathogens, and chloramphenicol has no preferred role in community-acquired pneumonia in current guidelines.
Option B: Option B is incorrect because chloramphenicol is not used as empiric therapy for septic shock; modern empiric regimens use beta-lactam/beta-lactamase inhibitor combinations, carbapenems, or antipseudomonal agents as appropriate, and the aplastic anemia risk makes chloramphenicol unsuitable for broad empiric use.
Option D: Option D is incorrect because chloramphenicol's myelosuppression is a dose-dependent toxicity, not an immunosuppressive tool, and it is not used in transplant conditioning regimens; using a drug with a risk of fatal aplastic anemia to suppress immune rejection would be pharmacologically irrational and clinically dangerous.
Option E: Option E is incorrect because chloramphenicol is not active against MRSA and is not used as an alternative to vancomycin for MRSA infections; while its hepatic metabolism does avoid renal dose adjustment issues, lack of MRSA activity disqualifies it from this role entirely.
10. A pharmacology lecturer asks students to identify the feature of oxazolidinone mechanism of action that distinguishes these antibiotics from all other clinically used ribosomal inhibitors. Which of the following most accurately describes the unique mechanistic property of linezolid and tedizolid?
A) They bind to the 50S subunit at the peptidyl transferase center and block elongation of the nascent peptide chain, the same catalytic step inhibited by chloramphenicol but at an adjacent binding site
B) They bind to the 30S subunit at the decoding site (A site) and cause misreading of the messenger RNA codon, producing aberrant and nonfunctional proteins that are toxic to the bacterium
C) They inhibit transpeptidation by covalently cross-linking the nascent peptide chain to the ribosome, permanently inactivating the ribosomal complex and producing bactericidal activity against all Gram-positive organisms
D) They intercalate into the ribosomal RNA at both the 30S and 50S subunits simultaneously, sterically blocking any new ribosomal assembly and selectively preventing re-initiation after translation of each mRNA is complete
E) They bind to the 23S rRNA of the 50S ribosomal subunit at a site that prevents formation of the functional 70S initiation complex — specifically blocking the assembly of the 30S initiation complex with the 50S subunit before translation can begin, acting at a pre-elongation step that no other antibiotic class targets
ANSWER: E
Rationale:
Oxazolidinones (linezolid, tedizolid) have a mechanism of action that is unique among all clinically used antibiotics: they act at the earliest possible step in protein synthesis — before elongation begins. They bind to the 23S rRNA of the 50S ribosomal subunit at a site that overlaps with both the A site and peptidyl transferase center, but their primary functional effect is to prevent the 30S initiation complex (containing mRNA and initiator fMet-tRNA) from assembling with the 50S subunit to form a functional 70S initiation complex. This blocks translation before it can begin. All other ribosomal inhibitors — macrolides, tetracyclines, aminoglycosides, chloramphenicol, and lincosamides — act during the elongation phase after the 70S complex is already assembled. Because the oxazolidinone binding site on the 50S subunit is distinct from those of macrolides, lincosamides, and chloramphenicol, ribosomal modification resistance mechanisms conferring resistance to those classes do not produce oxazolidinone cross-resistance.
Option A: Option A is incorrect because while oxazolidinones do bind to the 50S subunit, their primary mechanism is pre-initiation complex disruption, not elongation inhibition at the peptidyl transferase center; chloramphenicol acts during elongation, and describing oxazolidinones as acting at an adjacent site on the same step misrepresents their functionally distinct pre-initiation mechanism.
Option B: Option B is incorrect because binding to the 30S A site to cause codon misreading is the mechanism of aminoglycosides; oxazolidinones act on the 50S subunit and do not cause misreading of mRNA.
Option C: Option C is incorrect because covalent cross-linking of the nascent peptide to the ribosome is not a mechanism of any clinically used antibiotic class; oxazolidinones act reversibly, and their bacteriostatic (not universally bactericidal) activity against staphylococci and enterococci is inconsistent with permanent ribosomal inactivation.
Option D: Option D is incorrect because intercalation into rRNA simultaneously at both subunits is not a described mechanism for any antibiotic class, and oxazolidinones do not block re-initiation as a primary mechanism; they specifically prevent the initial formation of the 70S initiation complex, a mechanistically distinct event from the re-initiation described.
11. A hospitalist is considering linezolid for empiric therapy in a patient with a suspected healthcare-associated infection. A pharmacy student asks about the antimicrobial spectrum of oxazolidinones. Which of the following most accurately describes the spectrum of linezolid?
A) Linezolid has broad-spectrum activity against both Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli, making it useful for mixed infections
B) Linezolid is active exclusively against Gram-positive bacteria — including MRSA, VRSA, VRE (both E. faecalis and E. faecium), penicillin-resistant S. pneumoniae, and Mycobacterium tuberculosis — with no clinically useful activity against Gram-negative organisms because the drug cannot efficiently penetrate the Gram-negative outer membrane
C) Linezolid has activity primarily against anaerobic Gram-negative bacilli including Bacteroides fragilis, with limited activity against aerobic Gram-positive cocci such as staphylococci and enterococci
D) Linezolid is active against Gram-positive cocci but is specifically inactive against enterococci because VRE isolates constitutively express a ribosomal methyltransferase that prevents oxazolidinone binding to the 50S subunit
E) Linezolid has activity against Gram-positive organisms and select Gram-negative organisms including Haemophilus influenzae and Moraxella catarrhalis, but lacks activity against enteric Gram-negative bacilli and Pseudomonas
ANSWER: B
Rationale:
Oxazolidinones, including linezolid, are active exclusively against Gram-positive bacteria. They have no clinically useful activity against Gram-negative organisms because the outer membrane of Gram-negative bacteria acts as a permeability barrier that prevents oxazolidinones from reaching intracellular concentrations necessary for ribosomal inhibition. The Gram-positive spectrum includes MRSA, vancomycin-resistant S. aureus (VRSA), VRE (both E. faecalis and E. faecium), penicillin-resistant S. pneumoniae, and other streptococci. Linezolid is also active against Mycobacterium tuberculosis — exploiting its activity against mycobacterial 23S rRNA — and is a component of second-line regimens for extensively drug-resistant tuberculosis (XDR-TB). Activity against Nocardia species is also described. The Gram-positive-only spectrum must be understood when selecting linezolid empirically, as Gram-negative co-coverage always requires a second agent.
Option A: Option A is incorrect because linezolid has no clinically useful activity against Gram-negative organisms including P. aeruginosa, Klebsiella, or E. coli; using linezolid as the sole agent for suspected healthcare-associated infections without Gram-negative coverage would leave important pathogens untreated.
Option C: Option C is incorrect because linezolid's activity profile is the opposite of what is described; it is active against aerobic Gram-positive cocci (particularly MRSA and VRE) and has no useful activity against anaerobic Gram-negative bacilli such as B. fragilis.
Option D: Option D is incorrect because VRE (vancomycin-resistant Enterococcus) refers to vancomycin resistance via altered peptidoglycan precursor targets (van genes), not oxazolidinone resistance; linezolid retains activity against VRE because its ribosomal binding site is unaffected by the van gene-mediated resistance mechanism.
Option E: Option E is incorrect because while linezolid does lack activity against enteric Gram-negatives and Pseudomonas, it also does not have reliable activity against H. influenzae or M. catarrhalis at clinically achievable concentrations; its spectrum is restricted to Gram-positive organisms and mycobacteria.
12. A 58-year-old patient with MRSA pneumonia is responding well to IV linezolid after 5 days in the hospital. She has resumed eating and tolerating oral medications. The team discusses transitioning to oral therapy. Which pharmacokinetic property of linezolid most directly supports transitioning this patient from IV to oral linezolid at the same dose?
A) Linezolid has an oral bioavailability of approximately 100%, making the oral and intravenous formulations therapeutically equivalent at the same dose; a patient who can tolerate oral intake can be transitioned from IV to oral linezolid 600 mg every 12 hours with no change in systemic drug exposure
B) Linezolid undergoes extensive first-pass hepatic metabolism that converts a prodrug form to the active moiety; the oral formulation is therefore more bioavailable than the IV formulation because intestinal conversion is more efficient than plasma-phase conversion
C) Linezolid's volume of distribution is so small (less than 5 liters) that it remains confined to the vascular compartment; oral dosing achieves equivalent plasma concentrations because gastrointestinal absorption directly replenishes the central compartment
D) Oral linezolid achieves higher peak plasma concentrations than the IV formulation because gastrointestinal first-pass metabolism generates an active metabolite with a longer half-life, extending drug exposure beyond that of the parent compound
E) Linezolid is a substrate for intestinal P-glycoprotein efflux transporters, but hepatic CYP3A4 pre-systemic metabolism is negligible, so oral bioavailability approaches that of IV administration in most patients
ANSWER: A
Rationale:
Linezolid has an oral bioavailability of approximately 100% — one of the few antibiotics where oral and IV dosing are completely interchangeable without dose adjustment. A patient who starts on IV linezolid for MRSA pneumonia or bacteremia can be transitioned to oral 600 mg every 12 hours the moment they can tolerate oral intake, with no change in drug exposure or therapeutic effect. This property has significant clinical and health economic implications: oral linezolid eliminates the need for ongoing IV access, reduces nursing time and catheter-related infection risk, and allows earlier hospital discharge in appropriate patients. This is one of the key pharmacokinetic advantages of linezolid over vancomycin, which requires IV administration throughout treatment.
Option B: Option B is incorrect because linezolid is not a prodrug and does not undergo first-pass conversion to an active metabolite; it is absorbed as the active compound from the gastrointestinal tract, and its high bioavailability is due to efficient passive absorption, not metabolic activation during first pass.
Option C: Option C is incorrect because linezolid has a volume of distribution of approximately 40 to 50 liters — well above plasma volume — indicating substantial distribution into tissues; describing its distribution as confined to the vascular compartment is pharmacokinetically inaccurate.
Option D: Option D is incorrect because oral linezolid does not achieve higher peak plasma concentrations than IV through an active metabolite; linezolid's two metabolites are inactive oxidation products, and oral peak concentrations closely match IV peaks due to complete absorption without meaningful metabolic reduction.
Option E: Option E is incorrect because while linezolid has limited CYP3A4 metabolism (which is actually advantageous for avoiding drug interactions), the claim that oral bioavailability "approaches" IV is a significant understatement — it is essentially equivalent at approximately 100%, not merely approaching it; and P-glycoprotein efflux does not substantially limit linezolid absorption in clinical use.
13. A neurosurgical intensive care patient develops ventriculitis caused by MRSA following an external ventricular drain. The team is selecting an antibiotic with adequate CNS penetration. Regarding linezolid's pharmacokinetic properties relevant to CNS infection, which of the following is most accurate?
A) Linezolid does not penetrate the blood-brain barrier to a clinically meaningful extent because its large volume of distribution indicates preferential sequestration in peripheral tissues rather than CNS compartments
B) Linezolid achieves CNS concentrations equivalent to those of chloramphenicol because both drugs share the same lipophilicity and passive diffusion mechanism across the blood-brain barrier
C) Linezolid is actively transported into the CSF by the same organic anion transporter system that mediates beta-lactam CNS penetration, achieving CSF-to-plasma ratios that exceed 100% in the setting of meningeal inflammation
D) Linezolid achieves cerebrospinal fluid concentrations of approximately 66 to 70% of simultaneous plasma concentrations in patients with meningeal inflammation, representing good CNS penetration that supports its use for infections in the CNS caused by susceptible Gram-positive organisms
E) Linezolid's CSF penetration is negligible at standard oral doses but increases significantly with IV administration because parenteral dosing produces higher peak plasma concentrations that drive passive diffusion across the meninges
ANSWER: D
Rationale:
Linezolid achieves CSF concentrations of approximately 66 to 70% of simultaneous plasma concentrations in patients with meningeal inflammation — representing good CNS penetration for a drug of its molecular size and properties. This level of penetration supports its use for MRSA CNS infections including ventriculitis, brain abscess, and meningitis caused by susceptible Gram-positive organisms when vancomycin cannot be used or has produced inadequate CNS concentrations. Linezolid's oral bioavailability of approximately 100% also means oral step-down is possible once the patient is able to take medications by mouth, which is an advantage in prolonged CNS infection management.
Option A: Option A is incorrect because while linezolid has a volume of distribution of approximately 40 to 50 liters indicating substantial tissue distribution, this does not preclude CNS penetration; in fact, it indicates the drug distributes well into tissues including the CNS, and the CSF penetration data confirm useful concentrations are achieved.
Option B: Option B is incorrect because comparing linezolid to chloramphenicol's CNS penetration overstates linezolid's penetration; chloramphenicol achieves 30 to 50% of plasma even without inflammation (approaching 100% with inflammation), while linezolid achieves approximately 66 to 70% with inflammation — the mechanisms and penetration levels are different, and the two drugs should not be characterized as equivalent in CNS distribution.
Option C: Option C is incorrect because linezolid is not known to use organic anion transporters for active CNS uptake; beta-lactam CNS penetration relies on passive diffusion through inflamed meninges (many beta-lactams are actually excluded by active efflux), and CSF-to-plasma ratios exceeding 100% are not described for linezolid.
Option E: Option E is incorrect because linezolid's approximately 100% oral bioavailability means oral and IV dosing achieve equivalent plasma concentrations, and CSF penetration is not meaningfully different between routes; the premise that IV produces higher peaks sufficient to drive greater CSF penetration is pharmacokinetically inaccurate for linezolid at standard doses.
14. A clinical pharmacologist is comparing the drug interaction profiles of chloramphenicol and linezolid for a patient on multiple medications including an antiepileptic and an anticoagulant. Which of the following most accurately describes linezolid's cytochrome P450 interaction profile?
A) Linezolid is a potent inducer of CYP3A4 and CYP2C9, accelerating the metabolism of co-administered drugs metabolized by these enzymes and potentially reducing their therapeutic efficacy
B) Linezolid is a substrate and competitive inhibitor of CYP2D6, reducing the metabolism of drugs such as codeine and metoprolol and producing dose-dependent accumulation of their active metabolites
C) Linezolid does not undergo cytochrome P450 metabolism and does not inhibit or induce CYP enzymes; it is metabolized by non-enzymatic oxidation to two inactive metabolites, producing no CYP-mediated drug interactions
D) Linezolid inhibits CYP2C19 and CYP2C9 with potency comparable to chloramphenicol, making it equally problematic for patients on phenytoin or warfarin
E) Linezolid is metabolized exclusively by CYP3A4, and its own metabolism is subject to significant induction or inhibition by CYP3A4 modulators such as rifampin and azole antifungals
ANSWER: C
Rationale:
Linezolid is metabolized by non-enzymatic oxidation — not by cytochrome P450 enzymes — producing two inactive ring-opened morpholine metabolites that are eliminated in urine. Because linezolid neither undergoes CYP metabolism nor inhibits or induces CYP enzymes in clinically meaningful ways, it produces no CYP-mediated drug interactions. This is a significant pharmacokinetic advantage compared to chloramphenicol (which is a potent CYP2C19 inhibitor) and makes linezolid substantially safer for patients on multiple medications including narrow-therapeutic-index drugs like phenytoin, warfarin, cyclosporine, and statins. The drug interaction concern with linezolid is not CYP-based but rather pharmacodynamic — its monoamine oxidase (MAO) inhibition creates clinically significant interactions with serotonergic agents, a completely distinct mechanism from CYP enzyme interactions.
Option A: Option A is incorrect because linezolid is not a CYP inducer; it does not activate pregnane X receptor or induce CYP3A4, CYP2C9, or any other CYP isoform, and enzyme induction is not a mechanism of any linezolid interaction.
Option B: Option B is incorrect because linezolid is not metabolized by or inhibitory toward CYP2D6; the pathway described — CYP2D6 competitive inhibition affecting codeine or metoprolol — does not apply to linezolid.
Option D: Option D is incorrect because linezolid does not inhibit CYP2C19 or CYP2C9 and cannot be compared to chloramphenicol in this respect; characterizing them as equally problematic for phenytoin and warfarin co-administration is incorrect — this is a critical pharmacokinetic distinction that affects clinical prescribing.
Option E: Option E is incorrect because linezolid is not a CYP3A4 substrate; it is not metabolized by CYP at all, and rifampin or azole antifungal co-administration does not meaningfully alter linezolid pharmacokinetics through CYP3A4 induction or inhibition.
15. A resident is comparing tedizolid to linezolid for treatment of a patient with acute bacterial skin and skin structure infection (ABSSSI) caused by MRSA. Which of the following best describes a pharmacokinetic feature that distinguishes tedizolid from linezolid?
A) Tedizolid is renally cleared unchanged and requires dose reduction in patients with creatinine clearance below 50 mL/min, whereas linezolid undergoes hepatic metabolism and requires no renal dose adjustment
B) Tedizolid achieves lower tissue concentrations than linezolid because its higher molecular weight limits passive diffusion into soft tissues, necessitating longer treatment courses to achieve equivalent bacterial kill
C) Tedizolid is a potent CYP3A4 inhibitor that significantly reduces the metabolism of co-administered drugs, whereas linezolid has no CYP interactions; this limits tedizolid's use in patients on complex medication regimens
D) Tedizolid has lower oral bioavailability than linezolid (approximately 60% versus 100%) and must therefore be administered intravenously in patients with severe soft tissue infections to ensure adequate drug exposure
E) Tedizolid is administered as the prodrug tedizolid phosphate, which is rapidly converted to the active tedizolid moiety by plasma phosphatases after oral or IV administration; it achieves oral bioavailability exceeding 90% and a half-life of approximately 12 hours that supports once-daily dosing, and is approved for a 6-day course for ABSSSI compared to linezolid's 10 to 14-day course
ANSWER: E
Rationale:
Tedizolid phosphate is a prodrug that is rapidly and efficiently converted to the active tedizolid by plasma and tissue phosphatases after oral or intravenous administration. It has oral bioavailability exceeding 90% and a half-life of approximately 12 hours — approximately twice that of linezolid (4.5 to 5.5 hours) — allowing once-daily dosing compared to linezolid's twice-daily regimen. The approved regimen for ABSSSI is 200 mg once daily for 6 days, compared to linezolid's 600 mg every 12 hours for 10 to 14 days for similar indications. Tedizolid also concentrates in macrophages at levels exceeding plasma concentrations, enhancing activity against intracellular staphylococci. No dose adjustment is required for renal or moderate hepatic impairment. These pharmacokinetic advantages contribute to a more convenient regimen and may reduce cumulative drug exposure, which is relevant to tolerability over a course of therapy.
Option A: Option A is incorrect because tedizolid does not require renal dose adjustment; unlike aminoglycosides or vancomycin, it is not primarily renally cleared unchanged, and the statement that linezolid requires no renal adjustment while tedizolid does is the reverse of the correct comparison — neither requires renal dose adjustment.
Option B: Option B is incorrect because tedizolid achieves good tissue concentrations including intracellular macrophage concentrations exceeding plasma levels; its tissue distribution is not limited by molecular weight in the manner described, and shorter rather than longer courses are a feature of its pharmacokinetic profile.
Option C: Option C is incorrect because tedizolid does not inhibit CYP3A4; like linezolid, it is not metabolized by CYP enzymes to a clinically meaningful extent and does not produce CYP-mediated drug interactions.
Option D: Option D is incorrect because tedizolid phosphate achieves oral bioavailability exceeding 90% — not 60% — making the oral and IV formulations therapeutically equivalent in a manner similar to linezolid's 100% oral bioavailability; the premise that IV administration is required for severe infections due to bioavailability concerns is incorrect.
16. A 47-year-old patient with MRSA osteomyelitis has been receiving linezolid 600 mg every 12 hours for 5 weeks. Routine laboratory testing reveals a platelet count of 68,000/mcL (reference range 150,000 to 400,000/mcL), down from a normal baseline at the start of therapy. Which of the following best describes the mechanism, expected course, and appropriate monitoring for this complication?
A) The thrombocytopenia represents an immune-mediated heparin-induced reaction triggered by linezolid's structural similarity to heparin; it will worsen with continued therapy and requires platelet transfusion as primary management
B) Linezolid causes dose- and duration-dependent myelosuppression through inhibition of mitochondrial protein synthesis in bone marrow precursor cells; thrombocytopenia is the most consistently observed hematologic toxicity and is fully reversible upon drug discontinuation; complete blood count (CBC) monitoring is recommended weekly for courses exceeding 2 weeks
C) The thrombocytopenia is an idiosyncratic immune reaction unrelated to duration or cumulative dose; it carries a mortality exceeding 50% if the drug is not immediately discontinued and replaced with an agent from a structurally unrelated antibiotic class
D) Linezolid-associated thrombocytopenia results from direct platelet aggregation induced by the drug's MAO inhibitor activity; it is worsened by co-administration of antiplatelet agents and is prevented by dosing linezolid at lower frequency in patients on aspirin
E) This is an expected and acceptable laboratory finding during prolonged linezolid courses; no monitoring or dose adjustment is required because platelet counts below 50,000/mcL are the threshold at which intervention is clinically warranted
ANSWER: B
Rationale:
Linezolid causes reversible, dose- and duration-dependent suppression of all hematopoietic cell lines through inhibition of mitochondrial protein synthesis in bone marrow precursor cells — the same mechanism responsible for the drug's antibacterial activity, since mitochondrial ribosomes are structurally similar to bacterial 70S ribosomes. Thrombocytopenia (low platelet count) is the most consistently observed hematologic toxicity, typically appearing after 10 to 14 days of therapy, and the risk increases with prolonged courses as in this patient (5 weeks). Anemia and leukopenia can also occur. The thrombocytopenia is fully reversible upon drug discontinuation in the vast majority of patients. Weekly CBC monitoring is recommended for courses exceeding 2 weeks to detect this complication before it reaches severe levels. Risk factors for more pronounced myelosuppression include renal impairment, baseline thrombocytopenia, and prolonged treatment duration. Tedizolid produces significantly less myelosuppression than linezolid in clinical trials, attributed to its lower daily dose and pharmacokinetics.
Option A: Option A is incorrect because linezolid-associated thrombocytopenia is not an immune-mediated heparin-like reaction; it results from mitochondrial toxicity in marrow precursors, not from structural similarity to heparin or platelet factor-4 antibody formation; platelet transfusion is not the primary management approach.
Option C: Option C is incorrect because linezolid myelosuppression is the opposite of idiosyncratic — it is predictably related to dose and duration; it also does not carry greater than 50% mortality, which describes chloramphenicol's aplastic anemia; recovery is expected with drug discontinuation.
Option D: Option D is incorrect because thrombocytopenia from linezolid is not caused by platelet aggregation through MAO inhibitory activity; MAO inhibition is responsible for serotonin syndrome in drug interactions, not for platelet count reduction; the mechanism described conflates two different toxicities.
Option E: Option E is incorrect because a platelet count of 68,000/mcL in a patient on linezolid is clinically significant and warrants assessment and likely drug discontinuation or change; the claim that no monitoring is needed until levels fall below 50,000/mcL underestimates the risk of continued decline and the availability of alternative MRSA agents.
17. A 55-year-old patient with major depressive disorder on sertraline (an SSRI) develops a VRE bacteremia and requires linezolid. The treating physician expresses concern about starting linezolid in this patient. Which of the following correctly identifies the mechanism and expected clinical consequence of this drug combination?
A) Linezolid inhibits CYP2D6, the primary enzyme responsible for sertraline metabolism, causing sertraline to accumulate to toxic concentrations and producing QTc prolongation and ventricular arrhythmias as the primary clinical manifestation
B) Linezolid and sertraline compete for the same serotonin transporter (SERT) binding site; when both agents occupy SERT simultaneously, they produce paradoxical transporter activation that floods the synapse with an abnormal serotonin-transporter complex
C) The combination is safe as long as linezolid is dosed at 300 mg every 12 hours rather than the standard 600 mg, because the serotonergic interaction is dose-dependent and sub-therapeutic linezolid concentrations do not inhibit MAO activity to a clinically relevant degree
D) Linezolid is a reversible, nonselective monoamine oxidase inhibitor (MAOI); when combined with sertraline (which blocks serotonin reuptake), serotonin accumulates in the synapse and can trigger serotonin syndrome, characterized by the triad of mental status changes, autonomic instability, and neuromuscular abnormalities including clonus, hyperreflexia, and myoclonus
E) The interaction risk is limited to IV linezolid because the oral formulation undergoes partial hepatic degradation before reaching systemic circulation, reducing its MAO inhibitory activity by approximately 40% and making oral linezolid safe for co-administration with SSRIs
ANSWER: D
Rationale:
Linezolid is a reversible, nonselective MAO inhibitor (MAOI). MAO is responsible for metabolizing serotonin, dopamine, and norepinephrine in neurons and the gut. When linezolid is combined with serotonergic medications — SSRIs (selective serotonin reuptake inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), tricyclic antidepressants (TCAs), meperidine, tramadol, or other MAOIs — serotonin accumulates and can trigger serotonin syndrome. The classic triad of serotonin syndrome consists of mental status changes (agitation, confusion), autonomic instability (hyperthermia, diaphoresis, tachycardia, hypertension), and neuromuscular abnormalities (clonus, hyperreflexia, tremor, myoclonus). Serotonin syndrome can be life-threatening. Linezolid is contraindicated with SSRIs unless the clinical benefit outweighs the risk and an adequate washout period has been observed for the serotonergic agent. When linezolid is urgently needed (as in life-threatening VRE infection), sertraline should ideally be discontinued, the washout observed if clinically feasible, and the patient monitored closely.
Option A: Option A is incorrect because linezolid does not inhibit CYP2D6 in clinically meaningful ways; the interaction between linezolid and sertraline is pharmacodynamic (MAO inhibition plus serotonin reuptake inhibition), not pharmacokinetic through CYP2D6; the clinical manifestation is serotonin syndrome, not QTc prolongation.
Option B: Option B is incorrect because the mechanism of serotonin syndrome in this combination is not competition at the serotonin transporter; linezolid does not bind to SERT, and no "paradoxical transporter activation" is a recognized pharmacological phenomenon.
Option C: Option C is incorrect because linezolid's MAO inhibitory activity is not sufficiently diminished at sub-therapeutic doses to make the combination safe; halving the dose would also compromise antibacterial efficacy against VRE, and no reduced-dose strategy has been validated for managing this interaction.
Option E: Option E is incorrect because linezolid has approximately 100% oral bioavailability and does not undergo meaningful pre-systemic hepatic degradation; oral and IV linezolid have equivalent pharmacokinetics, so there is no basis for claiming oral linezolid is safer with respect to MAO inhibition.
18. A 38-year-old patient with extensively drug-resistant tuberculosis (XDR-TB) has been receiving linezolid for 8 months as part of a salvage regimen. He reports progressive numbness and tingling in his feet and blurred central vision with difficulty distinguishing colors. Which of the following best describes the mechanism of these complications and the recommended management strategy for patients requiring prolonged linezolid therapy?
A) Prolonged linezolid therapy is associated with peripheral neuropathy presenting as distal paresthesias and sensory loss, and optic neuropathy with visual loss, color vision disturbance, and central scotoma; both result from mitochondrial dysfunction in neurons; monthly ophthalmologic and neurological monitoring is recommended for courses exceeding 4 weeks, and pyridoxine (vitamin B6) supplementation may partially mitigate neurotoxicity through an incompletely understood mechanism
B) The neuropathy described is caused by linezolid's inhibition of folate synthesis in Schwann cells, producing demyelination analogous to that seen with methotrexate; folinic acid supplementation (leucovorin) is the standard treatment to reverse and prevent ongoing nerve injury
C) Linezolid produces an immune-mediated vasculitic neuropathy by generating reactive oxygen species that damage vasa nervorum; high-dose corticosteroids are the primary treatment, with linezolid continuation possible if steroid therapy is initiated promptly
D) The peripheral neuropathy reflects linezolid's accumulation in dorsal root ganglion cells due to their high lipid content; stopping linezolid will not reverse existing neuropathy because the drug is permanently incorporated into neuronal membranes, but dose reduction to 300 mg every 12 hours prevents further progression
E) These complications reflect linezolid-induced B12 deficiency caused by inhibition of methionine synthase in neural tissue; monthly cyanocobalamin injections are required to prevent progression, and supplementation fully reverses both peripheral and optic neuropathy within 4 to 6 weeks
ANSWER: A
Rationale:
Prolonged linezolid therapy — generally courses exceeding 28 days, and especially the multi-month courses used in XDR-TB — is associated with peripheral neuropathy (distal paresthesias and sensory loss in a stocking-glove distribution) and optic neuropathy (progressive visual loss, color vision disturbance, central scotoma). Both are mechanistically linked to mitochondrial dysfunction in neurons — the same underlying mechanism as linezolid's myelosuppression — reflecting inhibition of mitochondrial protein synthesis in neurons, which have high mitochondrial energy demands. Peripheral neuropathy may be irreversible if treatment is not stopped promptly; optic neuropathy can result in permanent vision impairment. Monthly ophthalmologic and neurological assessment are recommended for courses exceeding 4 weeks. Pyridoxine (vitamin B6) supplementation is used in XDR-TB patients on prolonged linezolid courses, as it may partially mitigate neurotoxicity, though the mechanism is not fully established.
Option B: Option B is incorrect because linezolid does not inhibit folate synthesis; it acts on the ribosome, not on folate pathway enzymes; folinic acid supplementation is used for methotrexate and trimethoprim toxicity, not for linezolid neuropathy.
Option C: Option C is incorrect because linezolid neuropathy is not immune-mediated vasculitic injury; it is a direct mitochondrial toxicity, and corticosteroids are not part of the management of linezolid-associated neuropathy; continuing linezolid on steroids would not prevent ongoing mitochondrial damage.
Option D: Option D is incorrect because while linezolid's peripheral neuropathy may be partially irreversible, this is not because the drug is permanently incorporated into neuronal membranes; stopping linezolid can halt and allow partial recovery, and dose reduction to 300 mg every 12 hours is not a validated strategy for preventing neuropathy while maintaining adequate anti-tuberculosis activity.
Option E: Option E is incorrect because linezolid neuropathy is not caused by B12 deficiency or inhibition of methionine synthase; B12 deficiency causes subacute combined degeneration of the spinal cord through a distinct mechanism, and cyanocobalamin supplementation does not treat or reverse linezolid-associated mitochondrial neuropathy.
19. A 66-year-old patient with a tunneled dialysis catheter develops fever and blood cultures grow MRSA. The covering intern asks whether linezolid can be used, noting that linezolid has shown superiority to vancomycin in MRSA pneumonia. The attending physician corrects this reasoning. Which of the following best explains why linezolid is not the preferred agent for MRSA bacteremia?
A) Linezolid cannot be used in bacteremia because it is renally cleared and produces toxic plasma concentrations in dialysis-dependent patients, making vancomycin the safer choice due to its well-established dosing protocols in renal failure
B) Linezolid's once-daily dosing makes peak bactericidal concentrations insufficient to clear organisms from the bloodstream; twice-daily dosing would overcome this limitation but is not approved for bacteremia
C) Linezolid is bacteriostatic against Staphylococcus aureus including MRSA; clinical trial data demonstrate inferior outcomes compared to vancomycin and daptomycin for MRSA bloodstream infections, thought to be related to the inability of a bacteriostatic agent to reliably clear bacteremia and prevent embolic complications; bactericidal therapy is required for MRSA bacteremia
D) Linezolid distributes poorly into blood and the vascular endothelium, with CSF concentrations substantially exceeding blood concentrations; this pharmacokinetic profile makes it pharmacodynamically unsuitable for bloodstream infections
E) Linezolid is contraindicated in bacteremia by FDA labeling because of an increased rate of all-cause mortality observed in a prospective trial of Gram-positive bacteremia that included organisms other than MRSA; this contraindication extends to all bacteremia regardless of pathogen
ANSWER: C
Rationale:
Linezolid's bacteriostatic activity against S. aureus — including MRSA — is the fundamental pharmacological reason it is not recommended for MRSA bacteremia. Infections of the bloodstream, endocarditis, and other deep-seated staphylococcal infections require bactericidal therapy for reliable cure and prevention of metastatic complications such as septic emboli, endocarditis, and osteomyelitis seeding. Clinical trial data (including MRSA bacteremia studies) show inferior outcomes with linezolid compared to vancomycin or daptomycin for bloodstream infections. The ZEPHYR trial demonstrated linezolid's superiority to vancomycin specifically for MRSA pneumonia — partly attributable to better lung penetration and more predictable pharmacokinetics — but this superiority does not extend to bacteremia. Using linezolid for MRSA bacteremia based on its pneumonia performance is a recognized prescribing error. Vancomycin and daptomycin are the agents of choice for MRSA bloodstream infections.
Option A: Option A is incorrect because linezolid does not require renal dose adjustment and its renal clearance profile does not produce toxic accumulation in dialysis patients; the reason to avoid linezolid in bacteremia is bacteriostatic activity, not renal dosing concerns.
Option B: Option B is incorrect because linezolid does not have a once-daily dosing schedule — it is dosed 600 mg every 12 hours; the rationale for avoiding it in bacteremia is not dosing frequency but rather bacteriostatic versus bactericidal activity against staphylococci.
Option D: Option D is incorrect because linezolid distributes well throughout the body with a volume of distribution of approximately 40 to 50 liters and achieves good tissue concentrations; the characterization that it distributes poorly into blood is pharmacokinetically inaccurate, and the described CSF-versus-blood distribution profile is not a basis for its clinical limitations in bacteremia.
Option E: Option E is incorrect because while there is clinical trial data showing inferior linezolid outcomes in Gram-positive bacteremia, the limitation on linezolid use in bacteremia is driven by clinical evidence and the bacteriostatic mechanism — not a blanket FDA labeling contraindication against all bacteremia; the framing in this option overstates the regulatory basis for avoiding linezolid.
20. A clinical microbiologist reports a linezolid-resistant MRSA isolate from a patient who received prolonged linezolid therapy for osteomyelitis. During a teaching conference, the resistance mechanisms underlying oxazolidinone resistance are reviewed. Which of the following correctly describes the primary mechanisms of acquired oxazolidinone resistance in staphylococci and enterococci?
A) Resistance is primarily mediated by upregulation of efflux pumps in the MFS (major facilitator superfamily) that actively export linezolid from the bacterial cytoplasm before it can reach the ribosome, analogous to tetracycline resistance
B) Resistance results from enzymatic inactivation of linezolid by a bacterial acetyltransferase that modifies the oxazolidinone ring, rendering the drug unable to bind to the 50S ribosomal subunit
C) Resistance develops through mutations in the gene encoding the 50S ribosomal protein L3, which physically displaces the oxazolidinone binding pocket and prevents drug-ribosome contact through steric exclusion
D) Resistance is caused by acquisition of the vanA gene cluster, which modifies the ribosomal target analogously to its role in vancomycin resistance, producing cross-resistance to all ribosomal inhibitors including macrolides and lincosamides
E) The dominant resistance mechanisms are point mutations in the 23S rRNA gene at positions including 2447, 2504, and 2576, which reduce drug-ribosome affinity; and acquisition of the cfr gene, which encodes an rRNA methyltransferase that methylates adenine at position 2503 (A2503) in the 23S rRNA and confers transferable cross-resistance to chloramphenicol and oxazolidinones
ANSWER: E
Rationale:
Oxazolidinone resistance in clinical isolates of staphylococci and enterococci occurs through two main mechanisms. First, point mutations in the 23S rRNA gene — particularly at positions 2447, 2504, and 2576 — reduce the affinity of the drug for its ribosomal binding site. Because bacteria carry multiple copies of the 23S rRNA gene, high-level resistance requires accumulation of mutations in multiple gene copies simultaneously, which limits the rate of emergence in organisms with fewer rRNA operon copies. Staphylococci carry 5 to 6 copies and can progressively accumulate mutations, particularly during prolonged therapy. Second, the cfr (chloramphenicol-florfenicol resistance) gene encodes an rRNA methyltransferase that methylates the adenine residue at position A2503 in the 23S rRNA, reducing binding of both chloramphenicol and oxazolidinones. The cfr gene is transferable on mobile genetic elements, enabling horizontal spread of resistance. Tedizolid retains activity against some linezolid-resistant isolates with single 23S rRNA mutations but not against cfr-positive isolates.
Option A: Option A is incorrect because active efflux is not the primary mechanism of clinically observed linezolid resistance in staphylococci and enterococci; ribosomal target modification (23S rRNA mutations and cfr methylation) is the dominant mechanism, not MFS-type efflux pump upregulation.
Option B: Option B is incorrect because enzymatic inactivation of the oxazolidinone ring by an acetyltransferase is not a clinically established resistance mechanism for linezolid; enzymatic inactivation is a major resistance mechanism for aminoglycosides and chloramphenicol (acetyltransferase, phosphotransferase, nucleotidyltransferase), but not for oxazolidinones.
Option C: Option C is incorrect because while mutations in ribosomal protein L3 have been described in some resistant isolates, they are not the dominant clinical resistance mechanism; the primary mechanisms are 23S rRNA point mutations and cfr gene acquisition, and characterizing L3 mutations as primary overstates their clinical significance.
Option D: Option D is incorrect because the vanA gene cluster modifies peptidoglycan precursor D-Ala-D-Ala to D-Ala-D-Lac, conferring vancomycin resistance — it has no effect on the ribosome and no role in oxazolidinone resistance; vancomycin resistance and linezolid resistance are mechanistically unrelated.
21. During rounds, a pulmonary attending mentions that a pivotal clinical trial demonstrated linezolid's superiority over vancomycin for a specific MRSA infection type, and asks residents to identify the trial and the proposed mechanism of advantage. Which of the following correctly identifies the trial and the primary pharmacological basis for linezolid's superior outcome in that study?
A) The ESTABLISH-1 trial demonstrated linezolid's superiority to vancomycin for MRSA bacteremia; the mechanism was linezolid's bactericidal activity against MRSA in the bloodstream combined with its ability to penetrate intravascular biofilm on vascular endothelium
B) The ZEPHYR trial demonstrated linezolid's superiority to vancomycin for MRSA nosocomial pneumonia including ventilator-associated pneumonia; proposed mechanisms include linezolid's better lung epithelial lining fluid penetration and more predictable pharmacokinetics compared to vancomycin's variable concentration-dependent dosing requirements
C) The ATTAIN trial demonstrated linezolid's superiority to vancomycin for MRSA skin and soft tissue infections; the mechanism was linezolid's direct inhibition of staphylococcal toxin production at sub-inhibitory concentrations, reducing local tissue destruction independent of its bacteriostatic activity
D) The CHAMPION trial demonstrated linezolid's superiority to vancomycin for MRSA endocarditis; the mechanism was linezolid's ability to penetrate fibrin vegetations on cardiac valves more effectively than vancomycin, which is excluded from vegetations by its large molecular size
E) The DAPTOMYCIN trial demonstrated that linezolid was non-inferior to vancomycin for all serious MRSA infections including pneumonia and bacteremia; linezolid's advantage was confined to patients with vancomycin MIC creep greater than 1.5 mcg/mL, where its fixed pharmacokinetic profile provided consistent drug exposure
ANSWER: B
Rationale:
The ZEPHYR trial (Wunderink et al., Clinical Infectious Diseases, 2012) was a randomized controlled trial that demonstrated linezolid's superiority to vancomycin for MRSA nosocomial pneumonia, including ventilator-associated pneumonia (VAP). The proposed mechanisms for linezolid's advantage include: superior penetration into pulmonary epithelial lining fluid (ELF) where linezolid achieves concentrations several times higher than simultaneous plasma concentrations, compared to vancomycin's more limited and variable lung penetration; more predictable pharmacokinetics (fixed dose versus vancomycin's weight- and renal function-dependent dosing with frequent monitoring needs); and possibly direct inhibition of MRSA virulence factor production at sub-inhibitory concentrations. Importantly, this superior performance for MRSA pneumonia does not extend to MRSA bacteremia, where linezolid's bacteriostatic activity produces inferior outcomes compared to vancomycin or daptomycin.
Option A: Option A is incorrect because ESTABLISH-1 (Prokocimer et al., JAMA, 2013) was a trial of tedizolid versus linezolid for ABSSSI — not a linezolid-versus-vancomycin bacteremia trial; and linezolid is specifically not recommended for MRSA bacteremia due to bacteriostatic activity producing inferior outcomes.
Option C: Option C is incorrect because while linezolid does inhibit staphylococcal toxin production at sub-inhibitory concentrations, there is no major trial called "ATTAIN" demonstrating its superiority for MRSA SSTI over vancomycin; ATTAIN was a trial of telavancin; the description mislabels both the trial and its findings.
Option D: Option D is incorrect because there is no "CHAMPION trial" demonstrating linezolid superiority for MRSA endocarditis over vancomycin; endocarditis caused by MRSA is in fact one of the settings where linezolid is specifically not recommended due to its bacteriostatic activity, and clinical evidence does not support its use for endocarditis.
Option E: Option E is incorrect because linezolid's ZEPHYR superiority was specific to MRSA pneumonia, not all serious MRSA infections including bacteremia; the non-inferiority framing and vancomycin MIC creep threshold described are not accurate characterizations of the clinical evidence for linezolid versus vancomycin.
22. A resident preparing a pharmacy and therapeutics committee presentation compares tedizolid and linezolid. Which of the following best summarizes the clinically meaningful pharmacological advantages of tedizolid over linezolid?
A) Tedizolid has a broader Gram-negative spectrum than linezolid, including activity against Haemophilus influenzae and Moraxella catarrhalis, making it preferable for respiratory infections where atypical and Gram-negative pathogens may co-exist with Gram-positive organisms
B) Tedizolid has no monoamine oxidase inhibitory activity and therefore carries no risk of serotonin syndrome when combined with SSRIs or SNRIs, making it the preferred oxazolidinone for patients on serotonergic antidepressants without any need for washout or monitoring
C) Tedizolid is bactericidal against MRSA in contrast to linezolid's bacteriostatic activity; this bactericidal property makes it appropriate for MRSA bacteremia when vancomycin or daptomycin cannot be used
D) Tedizolid is approximately 4 to 8 times more potent than linezolid against staphylococci and enterococci by MIC (minimum inhibitory concentration), supports once-daily dosing due to its longer half-life of approximately 12 hours, produces significantly less myelosuppression than linezolid in clinical trials, and requires no dose adjustment for renal or moderate hepatic impairment
E) Tedizolid retains full activity against all linezolid-resistant isolates regardless of resistance mechanism, including cfr-positive staphylococci, because its prodrug activation by plasma phosphatases produces a structurally distinct active moiety that binds to a different 50S subunit site than linezolid
ANSWER: D
Rationale:
Tedizolid offers several clinically meaningful pharmacological advantages over linezolid. It is approximately 4 to 8 times more potent than linezolid against staphylococci and enterococci by MIC, which allows the lower 200 mg once-daily dose to achieve equivalent or superior antibacterial effect compared to linezolid's 600 mg twice daily. Its half-life of approximately 12 hours — roughly twice that of linezolid (4.5 to 5.5 hours) — supports once-daily dosing, which is more convenient and reduces cumulative drug exposure over a treatment course. Tedizolid produces significantly less myelosuppression (particularly thrombocytopenia) than linezolid in clinical trials, attributed to its lower daily dose and once-daily pharmacokinetics reducing total mitochondrial exposure. No dose adjustment is required for renal or moderate hepatic impairment. For ABSSSI, the approved 6-day course compares favorably to linezolid's 10 to 14-day course.
Option A: Option A is incorrect because tedizolid, like linezolid, has no clinically useful activity against Gram-negative organisms including H. influenzae and M. catarrhalis; the Gram-positive-only spectrum is a class property of oxazolidinones, not a limitation unique to linezolid.
Option B: Option B is incorrect because tedizolid also inhibits MAO and the risk of serotonin syndrome with serotonergic combinations, while potentially lower based on available data, is still present and cannot be dismissed as zero risk; characterizing tedizolid as having no serotonin syndrome risk and safe for unrestricted co-administration with SSRIs without any monitoring or washout overstates the evidence.
Option C: Option C is incorrect because tedizolid is also bacteriostatic against MRSA, not bactericidal; the bacteriostatic class effect against staphylococci is shared by linezolid and tedizolid alike, and tedizolid is not recommended for MRSA bacteremia for the same reasons as linezolid.
Option E: Option E is incorrect because tedizolid does not retain activity against cfr-positive isolates; the cfr gene methylates A2503 in the 23S rRNA in a way that reduces oxazolidinone binding regardless of which specific oxazolidinone is used; tedizolid retains activity against some single 23S rRNA point-mutation isolates but not against cfr-positive organisms, which is an important clinical distinction.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.